| CAS NO: | 439239-90-4 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| Cas No. | 439239-90-4 |
| 别名 | 拉米地坦 |
| 化学名 | 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide |
| Canonical SMILES | CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F |
| 分子式 | C19H18F3N3O2 |
| 分子量 | 377.36 |
| 溶解度 | DMF: 25 mg/ml,DMSO: 25 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:20): 0.04 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lasmiditan is a selective agonist of 5-HT1F receptor with Ki value of 2.21nM [1]. Lasmiditan shows great selectivity against 5-HT1F over other human recombinant 5-HT receptor subtypes as well as other members of 5-HT1 family. The Ki values for 5-HT2A-2C, 5-HT6 and 5-HT7 are all above 2μM. In the in vitro functional assay, lasmiditan shows high functional selectivity for 5-HT1F with EC50 value of 43.1nM. Moreover, oral administration of lasmiditan potently decreases the dural plasma protein extravasation with ID50 value of 2×104μg/kg in the migraine models. It also inhibits trigeminal stimulation-induced c-fos expression in the nucleus caudalis. Furthermore, lasmiditan is proved to be an effective treatment in acute migraine after the phase II trials. And the oral administration is found to be better than the intravenous administration [1, 2] References: |
m.cnreagent.com